Search

Displaying results 8311 - 8320 of 10000 in total
  1. Drug

    Florasulam

    go.drugbank.com/drugs/DB15316
    Experimental

    Florasulam is under investigation in clinical trial NCT01193465 (Temperature and Humidity Among Different Anesthesia Work-station).

  2. Drug

    Thallium Tl-201

    go.drugbank.com/drugs/DB15361
    Investigational

    Thallium Tl-201 is under investigation in clinical trial NCT02697760 (The CZT Dynamic Myocardial Perfusion Imaging).

  3. Drug

    Rivenprost

    go.drugbank.com/drugs/DB16315
    Investigational

    Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).

  4. Drug

    DYN-101

    go.drugbank.com/drugs/DB17921
    Investigational

    DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.

  5. Drug

    Suvodirsen

    go.drugbank.com/drugs/DB17940
    Investigational

    Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.

  6. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

  7. Drug

    Leflutrozole

    go.drugbank.com/drugs/DB19047
    Investigational

    Leflutrozole is under investigation in clinical trial NCT02908074 (A 6 Month Safety Extension Study of MBGS205).

  8. Drug

    IMT-288

    go.drugbank.com/drugs/DB19068
    Investigational

    IMT-288 is under investigation in clinical trial NCT01730638 (Immunotep for Patients With Medullary Thyroid Carcinoma.).

    Synonyms: D-LYSINAMIDE, N-((4,7,10-TRIS(CARBOXYMETHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL)ACETYL)-D-TYROSYL-N6-(N-(4-((2-(1H-IMIDAZOL-4-YL)ETHYL)AMINO)-1,4-DIOXOBUTYL)GLYCYL)-D-LYSYL-D-.ALPHA., -GLUTAMYL-N6-(N-(4-((2-(1H-IMIDAZOL-4-YL)ETHYL)AMINO)-1,4-DIOXOBUTYL)GLYCY
  9. Drug

    Ensovibep

    go.drugbank.com/drugs/DB19078
    Investigational

    Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19).

  10. Drug

    REM-422

    go.drugbank.com/drugs/DB19304
    Investigational

    REM-422 is an orally bioavailable, small molecule mRNA degrader of the proto-oncogene c-Myb.